Bortezomib Injection IP

Name: Bortezomib Injection IP
Brand: NEETCO BIOPHARMA
Price: 600 INR
Availability: InStock

Price 600 INR/ Vial

Get a Price/Quote

MOQ : 1 Vial

Bortezomib Injection IP Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Dosage Form
Injection

Salt Composition
Bortezomib

Enzyme Types
Proteasome Inhibitor

Feature
Lyophilized powder for reconstitution

Ingredients
Bortezomib (as base), Mannitol, Nitrogen

Application
Anti-cancer therapy

Ph Level
Neutral

Physical Color/Texture
White to off-white lyophilized powder

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits 26S proteasome

Storage Instructions
Store below 25C, protect from light

Shelf Life
24 months

Solubility
Soluble in 0.9% NaCl solution

Prescription Status
Prescription only medicine

Compatibility
Compatible with most standard diluents

Container Type
Glass vial, rubber stopper, aluminium cap

Route of Administration
Intravenous or subcutaneous use only

Hazard Statement
Cytotoxic handle with appropriate precautions

Regulatory Status
WHO GMP certified manufacturing

Pack Size
1 vial of 2 mg or 3.5 mg

Reconstitution
Required prior to use, reconstitute with 0.9% sodium chloride injection

USP
High purity and stability

About Bortezomib Injection IP

Experience the rarefied excellence of Bortezomib Injection IP, specially formulated for splendiferous outcomes in anti-cancer therapy. Available in superlative pack sizes of 2 mg or 3.5 mg glass vials, each unit undergoes stringent promotional clearance for superior purity and stability. Suitable for intravenous or subcutaneous administration, this lyophilized powder reconstitutes effortlessly with 0.9% sodium chloride. As a prescription-only medicine, it guarantees maximum potency, certified by WHO GMP. Compatible with most diluents, cytotoxic handling precautions are paramount. A premier pick for Multiple Myeloma and Mantle Cell Lymphoma therapy.

Directions and Features of Bortezomib Injection IP

Bortezomib Injection IP is administered intravenously or subcutaneously after meticulous reconstitution with 0.9% sodium chloride. Each glass vial features a secure rubber stopper and aluminium cap, ensuring sterility and protection. The lyophilized white to off-white powder is odorless and compatible with common infusion equipment. Designed for anti-cancer therapy, it is a proteasome inhibitor, targeting the 26S proteasome for maximum effect. Store below 25C, shielded from light to maintain its superlative stability.

Export Market Reach, Payment, and Supply Ability

Bortezomib Injection IP is handed over reliably to clients across leading export markets, including Asia, Africa, and America. We offer flexible payment terms and high supply ability for seamless business transactions. Shipments are carefully freighted, ensuring WHO GMP-certified standards upon arrival. Every vial is shipped in secure packaging to guarantee product integrity during transit, making us a trusted distributor, supplier, and trader, with prompt handover for your urgent needs.

FAQ's of Bortezomib Injection IP:

Q: How should Bortezomib Injection IP be reconstituted prior to administration?

A: Bortezomib Injection IP should be reconstituted with 0.9% sodium chloride injection before use, following approved procedures for intravenous or subcutaneous administration.

Q: What are the main benefits of using Bortezomib Injection IP in anti-cancer therapy?

A: Bortezomib Injection IP offers high purity and stability, targeting the 26S proteasome for potent treatment of Multiple Myeloma and Mantle Cell Lymphoma.

Q: When is Bortezomib Injection IP prescribed to patients?

A: Bortezomib Injection IP is prescribed as a cytotoxic medicine exclusively for patients diagnosed with Multiple Myeloma or Mantle Cell Lymphoma, upon a specialist's recommendation.

Q: Where should Bortezomib Injection IP be stored to maintain its efficacy?

A: It should be stored below 25C and protected from light in its original packaging to preserve its quality and shelf life.

Q: What precautions must be taken during the handling and administration process?

A: Due to its cytotoxic nature, it is crucial to handle Bortezomib Injection IP with appropriate protective measures, following safety protocols for cytotoxic agents.

Q: How is Bortezomib Injection IP supplied to global export markets?

A: The product is shipped via secure freight methods to main export destinations. Payment terms are flexible and supply is robust to meet international demand.

Tell us about your requirement